Breast Cancer Clinical Trial
Official title:
Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may
fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use
different ways to stop tumor cells from dividing so they stop growing or die. Combining
chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which
treatment regimen is more effective for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during
or after combination chemotherapy or hormone therapy alone in treating perimenopausal or
postmenopausal women who have stage II or stage IIIA breast cancer.
OBJECTIVES: I. Compare overall survival and local and systemic disease-free survival
produced by adjuvant chemoendocrine therapy with 4 courses of anthracycline/cyclophosphamide
and concurrent vs. sequential tamoxifen (TMX) or toremifene (TOR) in peri- and
postmenopausal women with node-positive breast cancer who are considered suitable for
endocrine therapy alone. II. Evaluate these same endpoints in patients randomized to
chemoendocrine therapy vs. endocrine therapy alone. III. Evaluate these same endpoints in
patients randomized to TMX vs. TOR as the endocrine therapy agent. IV. Compare the quality
of life of patients treated on these regimens. V. Compare the toxic effects of these
regimens.
OUTLINE: This is a randomized study. Patients are stratified by type of primary therapy and
participating institution. Therapy must begin within 6 weeks of surgery. Patients in the
first group receive doxorubicin (or epirubicin) and cyclophosphamide every 28 days for a
total of 4 cycles and oral tamoxifen daily for 5 years, beginning day 1 of chemotherapy.
Patients in the second group receive the same chemotherapy with oral tamoxifen initiated on
day 8 of the fourth chemotherapy cycle and continued for 5 years. Patients in the third
group receive oral tamoxifen daily for 5 years. Patients in the fourth group are treated the
same as the first group, only tamoxifen is replaced by toremifene. Patients in the fifth
group are treated the same as the second group, only tamoxifen is replaced by toremifene.
Patients in the sixth group receive oral toremifene daily for 5 years. The timing of
optional radiotherapy for patients with less than total mastectomy in each group is based on
institutional policy; radiotherapy is administered for 5-6 weeks to the remaining breast
tissue, chest wall, and lung. Patients are followed every 3 months for 1 year, every 6
months for 2 years, and yearly thereafter.
PROJECTED ACCRUAL: 1,140 patients will be accrued over approximately 9 years, with 1
additional year of follow-up.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |